Oxford Covid vaccine could build immunity in older people – study
Phase 2 trial data shows strong immune response in over-70s and better tolerance in older adults
This is about the vaccine being developed jointly by AstraZeneca and the University of Oxford. It basically works the same way as the Pfizer and Moderna vaccines, teaching the body of the recipient to target the proteins in the 'spikes' that give the virus its name. It is therefore likely to show efficacy comparable with those vaccines when its Phase 3 tests are reported on in a few weeks time. This vaccine is intended to be distributed at the lowest possible price about $3 -$4 per dose opposed to between $32 and $37 per dose for Moderna and about $20 for Pfizer, and to be made available worldwide as rapidly as possible. It only requires an ordinary 'cold chain' for storage, not 'super freezers' which make vaccines hard to distribute in less prosperous countries:
Anyway, here is the main report referred to above.We have already started manufacturing the vaccine so that, should clinical trials prove successful and the vaccine be approved by regulators, it will be available to support broad and equitable access.
To produce billions of doses of a potential vaccine for markets around the world, we have built more than a dozen regional supply chains to provide rapid access to as many countries as possible, as quickly as possible following regulatory approval, while reducing transportation and any potential export or importation constraints. This network was designed with our broad understanding of global supplier capabilities, combined with a focus on local manufacturing where possible and a drive to balance speed of supply with affordable costs.
The University of Oxford is expected to release data on the efficacy of its coronavirus vaccine candidate in the coming weeks, with the latest trial results suggesting it produces a strong immune response in older adults.
The ChAdOx1 nCov-2019 vaccine has been shown to trigger a robust immune response in healthy adults aged 56-69 and over 70. Phase 2 data published in the Lancet suggests one of the groups most vulnerable to serious illness and death from Covid-19 could build immunity, researchers say.
According to the researchers, the trial demonstrated similar immune responses across all three age groups – 18-55, 56-69, and 70 and over. The study of 560 healthy adults, including 240 over the age of 70, found that the vaccine is better tolerated in older people than in younger adults. Volunteers received two doses of the vaccine candidate or a placebo meningitis vaccine. No serious adverse health events related to the vaccine were seen in the participants.
The results are consistent with phase 1 data reported for healthy adults aged 18-55 earlier this year.
Dr Maheshi Ramasamy, an investigator in the Oxford Vaccine Group and a consultant physician, said: “Older adults are a priority group for Covid-19 vaccination, because they are at increased risk of severe disease, but we know that they tend to have poorer vaccine responses. “We were pleased to see that our vaccine was not only well tolerated in older adults, but also stimulated similar immune responses to those seen in younger volunteers. The next step will be to see if this translates into protection from the disease itself.”
The study’s lead author, Prof Andrew Pollard, from the University of Oxford, said: “Immune responses from vaccines are often lessened in older adults because the immune system gradually deteriorates with age, which also leaves older adults more susceptible to infections. As a result, it is crucial that Covid-19 vaccines are tested in this group who are also a priority group for immunisation.”
Researchers say their findings are promising as they show that older people are having a similar immune response to younger adults.
Ramasamy added: “The robust antibody and T-cell responses seen in older people in our study are encouraging. The populations at greatest risk of serious Covid-19 disease include people with existing health conditions and older adults. We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure.”
The study also found that the vaccine, being developed with AstraZeneca, was less likely to cause local reactions at the injection site and symptoms on the day of vaccination in older adults than in the younger group. Adverse reactions were mild – injection-site pain and tenderness, fatigue, headache, feverishness and muscle pain – but more common than seen with the control vaccine. Thirteen serious adverse events occurred in the six months after the first dose was given, none of which were related to either study vaccine.
The authors note some limitations to their study, including that the participants in the oldest age group had an average age of 73-74 and few underlying health conditions, so they may not be representative of the general older population, including those living in residential care settings or aged over 80. Phase 3 trials of the vaccine are ongoing, with early efficacy readings possible in the coming weeks.
UK authorities have placed orders for 100m doses of the vaccine – enough to vaccinate most of the population – should it receive regulatory approval.
Pfizer and BioNTech have announced that their vaccine candidate has shown 95% efficacy, and 94% in those aged 65 and over. Forty million doses of that vaccine have been bought by the UK, with rollout potentially starting in early December if the jab is given the green light by regulators.
This week the US biotech firm Moderna released data suggesting its vaccine has almost 95% efficacy.
It was on my phone news I check before going to bed.
